-
William Blair Downgrades Nkarta Inc. (NKTX) to Market Perform
-
Nkarta, Inc. (NKTX) Tops Q1 EPS by 2c, provides guidance
-
Nkarta Inc. (NKTX) PT Lowered to $14 at Stifel
-
H.C. Wainwright Reiterates Buy Rating on Nkarta Inc. (NKTX)
-
Nkarta Inc. (NKTX) PT Lowered to $14 at Stifel
-
Nkarta (NKTX) to cut 34% staff
-
Nkarta, Inc. (NKTX) Misses Q3 EPS by 2c, provides guidance
-
Nkarta Inc. (NKTX) PT Lowered to $20 at Mizuho
-
Nkarta Inc. (NKTX) PT Lowered to $22 at H.C. Wainwright
-
Raymond James Upgrades Nkarta Inc. (NKTX) to Strong Buy
-
Nkarta, Inc. (NKTX) Tops Q2 EPS by 13c
-
Nkarta (NKTX) Initiates Investigator-Sponsored Clinical Trial of NKX019
-
Nkarta (NKTX) Appoints Nadir Mahmood as President
-
H.C. Wainwright Reiterates Buy Rating on Nkarta Inc. (NKTX)
-
Nkarta (NKTX) Initiates Clinical Trial of NKX019
-
Nkarta (NKTX) Appoints George Vratsanos to its Board

